FENNEC PHARMACEUTICALS INC. Tax Withholding Paid on Stock Awards
FENNEC PHARMACEUTICALS INC. (FENC) reported Tax Withholding Paid on Stock Awards of $1.25 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-13
- FENNEC PHARMACEUTICALS INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $941.00K, a 850.51% increase year-over-year.
- FENNEC PHARMACEUTICALS INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $311.00K, a 2491.67% increase year-over-year.
- FENNEC PHARMACEUTICALS INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $26.00K, a 188.89% increase year-over-year.
- FENNEC PHARMACEUTICALS INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $50.00K, a 13.79% decline year-over-year.
- FENNEC PHARMACEUTICALS INC. payment, tax withholding, share-based payment arrangement for fiscal 2025 was $187.00K, a 6.25% increase from fiscal 2024.
- FENNEC PHARMACEUTICALS INC. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $176.00K, a 125.64% increase from fiscal 2023.
- FENNEC PHARMACEUTICALS INC. payment, tax withholding, share-based payment arrangement for fiscal 2023 was $78.00K, a 59.79% decline from fiscal 2022.
- FENNEC PHARMACEUTICALS INC. payment, tax withholding, share-based payment arrangement for fiscal 2022 was $194.00K.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $941.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.25M 10-Q · filed 2026-08-13 | $1.28M derived: sum of 3 quarters · filed 2026-08-13 | $1.33M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $311.00K 10-Q · filed 2026-05-14 | $337.00K derived: sum of 2 quarters · filed 2026-05-14 | $387.00K derived: sum of 3 quarters · filed 2026-05-14 | $486.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $76.00K derived: sum of 2 quarters · filed 2026-03-27 | $175.00K derived: sum of 3 quarters · filed 2026-08-13 | $187.00K 10-K · filed 2026-03-27 |
| 2025-09-30 | $50.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $149.00K derived: sum of 2 quarters · filed 2026-08-13 | $161.00K 10-Q · filed 2025-11-13 | $170.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $99.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $111.00K 10-Q · filed 2026-08-13 | $120.00K derived: sum of 3 quarters · filed 2026-08-13 | $178.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $12.00K 10-Q · filed 2026-05-14 | $21.00K derived: sum of 2 quarters · filed 2026-05-14 | $79.00K derived: sum of 3 quarters · filed 2026-05-14 | $169.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $67.00K derived: sum of 2 quarters · filed 2026-03-27 | $157.00K derived: sum of 3 quarters · filed 2026-03-27 | $176.00K 10-K · filed 2026-03-27 |
| 2024-09-30 | $58.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $148.00K derived: sum of 2 quarters · filed 2025-11-13 | $167.00K 10-Q · filed 2025-11-13 | $184.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $90.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $109.00K 10-Q · filed 2025-08-14 | $126.00K derived: sum of 3 quarters · filed 2025-08-14 | |
| 2024-03-31 | $19.00K 10-Q · filed 2025-05-14 | $36.00K derived: sum of 2 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $78.00K 10-K · filed 2025-03-26 | ||
| 2023-09-30 | $61.00K 10-Q · filed 2023-11-09 | |||
| 2023-03-31 | $20.00K 10-Q · filed 2024-05-14 | $48.00K derived: sum of 2 quarters · filed 2024-05-14 | ||
| 2022-12-31 | $28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $194.00K 10-K · filed 2024-03-29 | ||
| 2022-09-30 | $166.00K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |